BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
المؤلفون المشاركون
Peker, Yasar Subutay
Can, Mehmet Fatih
Ozerhan, Ismail Hakki
Yagci, Gokhan
Zeybek, Nazif
Kavakli, Kutan
Gurkok, Sedat
Gozubuyuk, Alper
Genc, Onur
Erdem, Gokhan
Ozet, Ahmet
Gerek, Mustafa
Peker, Yusuf
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-04-15
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
The main method of fighting against colon cancer is targeted treatment.
BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers.
In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient.
A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic.
The patient was evaluated and FOLFOX + bevacizumab treatment was initiated, which was then continued with vemurafenib.
A remarkable response was achieved with vemurafenib treatment in which the drug resistance occurred approximately in the sixth month.
Even though the patient benefited majorly from vemurafenib, he died on the 20th month of the diagnosis.
The expected overall survival for metastatic V600E mutant colon adenocarcinoma patients is 4.7 months.
BRAF inhibitors provide new treatment alternatives for V600E mutant colorectal cancers, with prolonged overall survival.
BRAF inhibitors in combination with MEK inhibitors are reported as feasible treatment to overcome BRAF inhibitor drug resistance on which phase studies are still in progress.
To conclude, BRAF inhibitors alone or in combination with other drugs provide a chance for curing BRAF V600E mutant colorectal cancer patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Peker, Yasar Subutay& Can, Mehmet Fatih& Ozerhan, Ismail Hakki& Yagci, Gokhan& Zeybek, Nazif& Kavakli, Kutan…[et al.]. 2018. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Case Reports in Surgery،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1151011
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Peker, Yasar Subutay…[et al.]. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Case Reports in Surgery No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1151011
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Peker, Yasar Subutay& Can, Mehmet Fatih& Ozerhan, Ismail Hakki& Yagci, Gokhan& Zeybek, Nazif& Kavakli, Kutan…[et al.]. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Case Reports in Surgery. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1151011
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1151011
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر